Modality
Fusion Protein
MOA
JAK1/2i
Target
TIM-3
Pathway
Notch
NSCLC
Development Pipeline
Preclinical
~Nov 2011
→ ~Feb 2013
Phase 1
~May 2013
→ ~Aug 2014
Phase 2
~Nov 2014
→ ~Feb 2016
Phase 3
~May 2016
→ ~Aug 2017
NDA/BLA
~Nov 2017
→ ~Feb 2019
Approved
May 2019
→ Mar 2030
ApprovedCurrent
NCT08026394
1,535 pts·NSCLC
2019-05→2030-03·Active
1,535 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-03-063.9y awayPh3 Readout· NSCLC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Active
Catalysts
Ph3 Readout
2030-03-06 · 3.9y away
NSCLC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08026394 | Approved | NSCLC | Active | 1535 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |